Ulf Petrausch

Dr. Ulf Petrausch

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013
Verified
Journal Article
Closed access
GJGopinadh Jakka
Gopinadh Jakka
PSPetra C Schuberth
Petra C Schuberth
MTMarkus Thiel
Markus Thiel
GHGerhard Held
Gerhard Held
FSFrank Stenner
Frank Stenner
UPUlf Petrausch
Ulf Petrausch

1 September 2019 in Therapeutische Umschau
Verified
Journal Article
Closed access
UPUlf Petrausch
Ulf Petrausch
Zusammenfassung. Die Checkpointblockade ist eine wichtige therapeutische Säule in der Behandlung von Patienten mit Krebserkrankungen geworden. Im Rahmen dieser Entwicklung der letzten 10 Jahre wurde klar, dass diese neue Substanzklasse aufgrund seiner immunmodulatorischen Eigenschaften ein ganz besonderes Nebenwirkungsprofil aufweist, dass ein spezielles Management der unerwünschten Wirkungen zur Folge haben muss. Nur das Wissen um diese unerwünschten Wirkungen erlaubt den therapeutischen und damit auch erfolgreichen Einsatz dieser Substanzklasse. Da die unerwünschten Wirkungen sehr unterschiedlich und zeitlich sehr versetzt auftreten können, muss das Wissen um diese unerwünschten Nebenwirkungen breit in den Behandlungsteams verteilt sein, damit Symptome der unerwünschten Nebenwirkungen rasch erkannt werden können und die entsprechenden Massnahmen in koordinierte Weise ergriffen werden können. Dieser Artikel möchte einen Beitrag zum besseren Erkennen und Management der unerwünschten Nebenwirkungen von Checkpoint-Inhibitoren leisten.

23 April 2024
Verified
Book Chapter
Closed access
PDF file
AGAndrea Gaisser
Andrea Gaisser
EDEveline Daetwyler
Eveline Daetwyler
SRSacha Rothschild
Sacha Rothschild
UPUlf Petrausch
Ulf Petrausch
Silvia HoferSilvia Hofer
Silvia Hofer
Bruno FuchsBruno Fuchs
Bruno Fuchs

23 April 2024
Verified
Book Chapter
Closed access
PDF file
UPUlf Petrausch
Ulf Petrausch
PJPatrick Patrick Jahn
Patrick Patrick Jahn

20 May 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
FPFlorian Posch
Florian Posch
KSKarina Silina
Karina Silina
UPUlf Petrausch
Ulf Petrausch
SLSebastian Leibl
Sebastian Leibl
AMAxel Muendlein
Axel Muendlein
TWThomas Winder
Thomas Winder
E15083 Background: The tumor immune infiltrate and organized lymphocytic aggregates within the tumor microenvironment, known as tertiary lymphoid structures (TLS), play a critical role in cancer. We hypothesize that the maturation stage of TLS harbors prognostic information on recurrence risk in patients (pts) with non-metastatic colorectal cancer (nmCRC). Methods: In a comprehensive immunofluorescence and clinical analysis of 111 pts with UICC stage II & III nmCRC (median age: 65 yrs; female: n = 53 (48%); stage III: n = 69 (62%)), we quantified the number and maturation status of tumor-associated TLS in baseline surgical specimens:[1] Early TLS (E-TLS, composed of dense lymphocytic aggregates without follicular dendritic cells (FDCs), [2] Primary follicle-like TLS (PFL-TLS, having FDCs but no germinal center (GC) reaction), and [3] Secondary follicle-like TLS (SFL-TLS, having an active GC reaction). The 3-year incidence of recurrence was the primary endpoint of this study, which occurred in 19 pts (3-year recurrence risk = 18.3%). Results: Most TLS formed in tissue adjacent to the tumor. The median number of TLS/mm of tumor perimeter was 1.0 [25th-75th percentile: 0.5-1.7]. The average proportions of different TLS maturation stages were 56% of E-TLS [40-78], 20% of PFL-TLS [6-37], and 16% of SFL-TLS [0-32]. A structural equation model was fitted to summarize the TLS counts and maturation stages into a TLS maturation immunoscore for predicting recurrence. 3-year recurrence risks were 31.7% (95%CI: 17.2-47.3), 15.9% (5.7-30.5), and 9.4% (2.4-22.4) in pts in the 1st, 2nd, and 3rd tertile of the score (Gray’s test p = 0.05). A higher score was significantly associated with a lower recurrence risk (Hazard ratio (HR) for 10 units increase = 0.76, 95%CI: 0.59-0.97, p = 0.03), and this association prevailed in multivariable analysis adjusting for age, ECOG performance status, stage, and adjuvant chemotherapy (Adjusted HR = 0.73, 0.54-0.99, p = 0.05). Conclusions: Tumors of nmCRC pts with a very low risk of recurrence are characterized by an increased fraction of mature TLS comprising FDCs and GCs. If confirmed prospectively, adjuvant chemotherapy may be avoided in nmCRC pts with a high TLS maturation score.

23 April 2024
Verified
Book Chapter
Closed access
PDF file
UPUlf Petrausch
Ulf Petrausch
AMAndreas Müller
Andreas Müller
TKThomas Kroner
Thomas Kroner